Corporate ProfileExicure, Inc. is a clinical stage biotechnology company developing a new class of immunomodulatory and gene regulating drugs against validated targets. Exicure's proprietary spherical nucleic acid (SNA™) architecture unlocks the potential of therapeutic oligonucleotides in a wide range of cells and tissues. Exicure's lead programsRead More
(Common Stock) Data as of 05/20/19 4:32 am EDT
Copyright West LLC. Minimum 15 minutes delayed.